Treatment of Basal cell carcinoma: Is intralesional methotrexate an option?

Treatment of Basal cell carcinoma: Is intralesional methotrexate an option?

J Dermatolog Treat. 2018 Mar 12;:1-11

Authors: Balighi K, Ansari MS, Mirzaiepour M, Daneshpazhooh M, Mahmoudi H

Abstract
Basal cell carcinoma (BCC) is the most common malignancy in the world. Surgery is treatment of the choice and other modalities such as topical and systemic agents have been used. In this study we evaluate intralesional methotrexate(MTX) effectiveness in treatment of BCC as an antimetabolite agent.MTX was injected into 40 nodular BCCs with 2.5mg/ml,10mg/ml and 25 mg/ml concentrations and rebiopsy was done 1 month later. There was no change in size and shape of lesions. Although MTX was safe and well tolerated, the study does not show any effect in treatment of BCC.

PMID: 29528258 [PubMed - as supplied by publisher]

http://ift.tt/2Do7Afz